Collector
Giriş Yap
GSK Makes Its Biggest Bet In More Than A Decade, Paying $10.6 Billion For Cancer Drug Developer Nuvalent | Collector
GSK Makes Its Biggest Bet In More Than A Decade, Paying $10.6 Billion For Cancer Drug Developer Nuvalent

GSK Makes Its Biggest Bet In More Than A Decade, Paying $10.6 Billion For Cancer Drug Developer Nuvalent

GSK will acquire Nuvalent for $10.6 billion to expand its lung cancer pipeline as Nuvalent shares surge nearly 39%. Importance Rank: 1 read more

Go to News Site